---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004192"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:53:16.464465+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Stoke updates STK-001 Dravet data timelines: 45mg mid-2023, 70mg H2 2023; STK-002 ADOA Phase 1/2 start 2024

## Summary
- Multiple-dose STK-001 45mg data expected mid-2023; 70mg data expected second half 2023.
- Phase 1/2a for Dravet syndrome to complete in 2023, enabling Phase 3 program in 2024.
- STK-002 for ADOA: UK CTA submission expected H1 2023; Phase 1/2 start planned for 2024.
- Updated corporate presentation posted ahead of J.P. Morgan Healthcare Conference.

## SEC filing metadata
- accession: 0001193125-23-004192
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312523004192/0001193125-23-004192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312523004192/d427248d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004192
- JSON: https://secwatch.observer/filing/0001193125-23-004192.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.